WallStSmart

Legend Biotech Corp (LEGN)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 6292% more annual revenue ($65.77B vs $1.03B). MRK leads profitability with a 13.6% profit margin vs -28.8%. MRK earns a higher WallStSmart Score of 50/100 (D+).

LEGN

Avoid

33

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.0Quality: 5.5
Piotroski: 2/9Altman Z: 0.67

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 3.3Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

LEGNUndervalued (+22.3%)

Margin of Safety

+22.3%

Fair Value

$23.87

Current Price

$28.12

$4.25 discount

UndervaluedFair: $23.87Overvalued
MRKOvervalued (-14.9%)

Margin of Safety

-14.9%

Fair Value

$97.76

Current Price

$111.38

$13.62 premium

UndervaluedFair: $97.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LEGN1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
64.2%10/10

Revenue surging 64.2% year-over-year

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$277.36B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

Areas to Watch

LEGN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-29.1%2/10

ROE of -29.1% — below average capital efficiency

Free Cash FlowQuality
$-126.56M2/10

Negative free cash flow — burning cash

MRK4 concerns · Avg: 3.3/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
5.282/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : LEGN

The strongest argument for LEGN centers on Revenue Growth. Revenue growth of 64.2% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : LEGN

The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

LEGN profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.

LEGN carries more volatility with a beta of 0.30 — expect wider price swings.

LEGN is growing revenue faster at 64.2% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 33/100). LEGN offers better value entry with a 22.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Legend Biotech Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?